新诊断转移性前列腺癌患者中非区域淋巴结与骨转移共存的预后重要性
该观察性队列研究基于荷兰癌症登记处2010-2018年新诊断的同步转移性激素敏感性前列腺癌(mHSPC)男性数据,评估非区域淋巴结(NRLN)与骨转移共存的预后意义,并判断M1b/M1c分型是否最合适。研究纳入超过5600例(2015年10月后诊断者可评估疾病体积)及超过14000例(2010-2018年队列)男性,主要终点为总生存期(OS)。结果显示,低体积同步mHSPC中NRLN与骨转移共存(现归为M1c)预后较差;但内脏转移(M1c)生存更差,提示将NRLN与骨转移共存归为M1c或M1b均不合适,应考虑在第九版TNM分类中增加第四个M1类别,并重新评估转移负荷定义。
要点
- 低体积同步mHSPC中,NRLN与骨转移共存(现为M1c)是预后不良标志。
- 内脏转移(M1c)的OS比NRLN与骨转移共存更差(HR 2.20)。
- 将NRLN与骨转移共存归为M1c或M1b均不合适,作者建议考虑新增M1类别。
核心结论
- 低体积同步mHSPC中,NRLN与骨转移共存(现归为M1c)是预后不良标志。
- 内脏转移(M1c)的生存比NRLN与骨转移共存更差。
- 将NRLN与骨转移共存归为M1c或M1b并不合适。
- 作者建议考虑在第九版TNM分类中增加第四个M1类别,并重新评估转移负荷定义。
研究设计与样本
- 观察性队列研究,基于荷兰癌症登记处2010-2018年新诊断的同步mHSPC男性。
- 按转移部位分为NRLN(M1a)、骨(M1b)、NRLN+骨(M1c)或内脏转移(M1c)。
- 2015年10月后诊断者可评估疾病体积,分析在超过5600例队列中进行,并在2010-2018年超过14000例队列中重复。
- 主要终点为总生存期(OS),采用Cox回归计算风险比(HR)。
主要发现
- 与NRLN+骨转移(参照组)相比,仅NRLN者OS更好(HR 0.70,95%CI 0.55-0.88)。
- 低体积亚组中仅骨转移者OS亦更好(HR 0.75,95%CI 0.58-0.98),但高体积亚组无显著差异(HR 0.99,95%CI 0.84-1.18)。
- 内脏转移者OS更差(HR 2.20,95%CI 1.75-2.77 + 0.97/月,95%CI 0.96-0.98)。
关键数值与推荐
- 仅NRLN vs NRLN+骨转移:HR 0.70(95%CI 0.55-0.88)。
- 低体积仅骨转移 vs NRLN+骨转移:HR 0.75(95%CI 0.58-0.98)。
- 高体积仅骨转移 vs NRLN+骨转移:HR 0.99(95%CI 0.84-1.18)。
- 内脏转移 vs NRLN+骨转移:HR 2.20(95%CI 1.75-2.77 + 0.97/月,95%CI 0.96-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the prognostic importance of concomitant non-regional lymph node (NRLN) and bone metastases in men with synchronous metastatic hormone-sensitive prostate cancer (mHSPC), and to determine whether M1b/M1c is the most appropriate M-stage and evaluate the additional importance to the distinction in low/high volume disease. PATIENTS AND METHODS: All men diagnosed with synchronous mHSPC from 2010 to 2018 in the Netherlands were identified in the Netherlands Cancer Registry. Men were categorised as having NRLN (M1a), bone (M1b), NRLN and bone (M1c), or visceral metastases (M1c). For men diagnosed since October 2015 disease volume could be determined. Analyses were performed in this cohort (>5600 men) and repeated in the 2010-2018 cohort (>14 000 men). The primary outcome measure in this observational cohort study was overall survival (OS) and Cox regression was used to calculate hazard ratios (HRs). RESULTS: Compared to men with NRLN and bone metastases (reference group), OS of men with only NRLN (HR 0.70, 95% confidence interval [CI] 0.55-0.88) was better. This was also true for men with only bone metastases in the low-volume subgroup (HR 0.75, 95% CI0.58-0.98), but not in the high-volume subgroup (HR 0.99, 95% CI 0.84-1.18). In contrast, the OS of men with visceral metastases was worse (HR 2.20, 95% CI 1.75-2.77 + 0.97/month, 95% CI 0.96-0.98). CONCLUSION: In men with low-volume synchronous mHSPC, presence of concomitant NRLN and bone metastases (currently classified as M1c), is a poor prognostic sign. However, survival of men with visceral metastases (M1c) is worse. Implying that classifying concomitant NRLN and bone metastases as M1c or M1b is not appropriate. Adding a fourth M1-category to the ninth edition of the Tumour-Node-Metastasis classification should be contemplated. Furthermore, definitions of metastatic burden need to be re-evaluated.
引用
- Heesterman BL, van der Poel HG, Schoots IG, et al. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. BJU Int. 2021. PMID: 34741789. doi:10.1111/bju.15632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。